BiotechTube

norelgestromin/ethinyl estradiol (NGMN/EE) transdermal contraceptive system.

Phase 1Completed
0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Female Contraception

Conditions

Female Contraception

Trial Timeline

May 1, 2004 → Aug 1, 2004

NCT ID
NCT00775086

About norelgestromin/ethinyl estradiol (NGMN/EE) transdermal contraceptive system.

norelgestromin/ethinyl estradiol (NGMN/EE) transdermal contraceptive system. is a phase 1 stage product being developed by Johnson & Johnson for Female Contraception. The current trial status is completed. This product is registered under clinical trial identifier NCT00775086. Target conditions include Female Contraception.

What happened to similar drugs?

2 of 15 similar drugs in Female Contraception were approved

Approved (2) Terminated (0) Active (13)
✅Eribulin Injection [Halaven] + Paclitaxel injectionEisaiApproved
✅CFA + rFSHMerckApproved
🔄Gemcitabine + liposomal doxorubicinEli LillyPhase 3
🔄Gemcitabine + Paclitaxel + CarboplatinEli LillyPhase 3
🔄Abemaciclib 50 MG; 150mg 1-0-1 per osEli LillyPhase 3
🔄SHR6390 + placeboJiangsu Hengrui MedicinePhase 3
🔄SHR7280；Ganirelix Acetate Injection simulant + SHR7280 simulant； Ganirelix Acetate InjectionJiangsu Hengrui MedicinePhase 3

Hype Score Breakdown

Clinical
6
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00775086Phase 1Completed

Competing Products

20 competing products in Female Contraception

See all competitors
ProductCompanyStageHype Score
FulvestrantDr. Reddy's LaboratoriesPre-clinical
19
Fulvestrant + AbemaciclibEli LillyPhase 2
39
Gemcitabine + liposomal doxorubicinEli LillyPhase 3
40
ASP3325 + PlaceboAstellas PharmaPhase 1
29
EnsitrelvirShionogiPhase 1
29
Eribulin Injection [Halaven] + Paclitaxel injectionEisaiApproved
39
Gemcitabine + Paclitaxel + CarboplatinEli LillyPhase 3
40
Abemaciclib 50 MG; 150mg 1-0-1 per osEli LillyPhase 3
44
Abemaciclib, durvalumab and aromatase inhibitorEli LillyPhase 1
21
Norgestimate/Ehinyl Estradiol; Folic acid.Johnson & JohnsonPhase 1
29
SHR6390 + placeboJiangsu Hengrui MedicinePhase 3
44
SHR7280 tabletsJiangsu Hengrui MedicinePhase 2
35
SHR7280；Ganirelix Acetate Injection simulant + SHR7280 simulant； Ganirelix Acetate InjectionJiangsu Hengrui MedicinePhase 3
40
SHR3162Jiangsu Hengrui MedicinePhase 1
25
AZD3293 + PlaceboAstraZenecaPhase 1
29
Fulvestrant 500mg + Palbociclib 125mg + Goserelin 3.6 MG + PlacebosAstraZenecaPhase 3
40
AZD2516 + PlaceboAstraZenecaPhase 1
29
Durvalumab + TremelimumabAstraZenecaPhase 2
39
Dapagliflozin + Metformin + Dapagliflozin + MetforminAstraZenecaPhase 1
29
AZD4901 (oral) + Placebo to match AZD4901AstraZenecaPhase 2
35